Automated Telephone Outreach with Speech Recognition Does Not Improve Colorectal Screening(2/11/2010) Researchers from Harvard University have reported that an automated telephone outreach with speech recognition (ATO-SR) program did not improve rates of screening for colorectal cancer (CRC). The details of this study were published in the February 8, 2010 issue of the Archives of Internal Medicine.
CT Colonography Safe and Effective in Older Individuals(2/8/2010) Researchers from the University of Wisconsin have reported that CT colonography is a safe and effective colorectal screening procedure in persons 65-79 years of age. The details of this study appeared in the February, 2010 issue of Radiology.
Human IgG Antibody Profiles May Detect Colorectal Cancer(1/20/2010) Researchers from Ireland have reported that human IgG antibody profiles may distinguish symptomatic patients with and without colorectal cancer. The details of this study appeared in the January, 2010 issue of Gut.
Folic Acid and Vitamin B12 Increase Risk of Cancer in Patients with Heart Disease(11/19/2009) Researchers from Norway have reported that folic acid and B12 supplements in patients with ischemic heart disease increase the risk of cancer and all-cause mortality. The details of this study appeared in the November 18, 2009 issue of the Journal of the American Medical Society.
Obesity Linked with Worse Colon Cancer Outcomes(3/16/2010) Researchers from the Mayo Clinic have reported that obese colon cancer patients have a higher risk of cancer recurrence and death than healthy-weight patients. The results of this study were published in the March 15, 2010 issue of Clinical Cancer Research.
XELOX Superior to 5-FU/LV for Adjuvant Treatment of Stage III Colon Cancer(2/25/2010) Researchers involved with the international randomized trial NO16968 have reported that the adjuvant XELOX regimen—Xeloda® (capecitabine) and Eloxatin® (oxaliplatin)—was superior to 5-FU and leucovorin (5-FU/LV) for Stage III colon cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.
Prior Regular Use of Nonsteroidal Anti-inflammatory Drugs Improves Survival of Patients with Colorectal Cancer(1/11/2010) Researchers affiliated with the California Teachers Study Group have reported that women with colorectal cancer who have a history of regular use of nonsteroidal anti-inflammatory drugs (NSAID) have an improved survival compared with non users. The details of this study appeared in the December 15, 2009 issue of Cancer.
Physical Activity Associated with Lower Risk of Death in Men with Localized Colorectal Cancer(12/22/2009) Researchers affiliated with the Health Professionals Follow-up Study have reported that physical activity was associated with a lower risk of colorectal cancer-specific and overall mortality in men with non-metastatic colorectal cancer. The details of this study appeared in the December 14/28 issue of the Archives of Internal Medicine.
Avastin® Not Contraindicated in Patients with CNS Metastases(3/8/2010) Researchers from France have reported that patients with central nervous system (CNS) metastases have similar rates of whether or not they receive Avastin® (bevacizumab). The details of this study appeared in the January 2010 issue of Clinical Cancer Research.
Vectibix® Improves Outcome of Previously Treated Colorectal Cancer(2/3/2010) Researchers involved in an international randomized trial have reported that the addition of Vectibix® (panitumumab) to FOLFIRI (5-fluorourcil, Camptosar® [irinotecan], and leucovorin) improves progression-free survival (PFS) in patients with colorectal cancer with wild-type KRAS who are receiving second-line therapy. These results were presented at the 2010 ASCO Gastrointestinal Cancers Symposium.
Review Confirms Effectiveness of Avastin® plus Chemotherapy in Advanced Colorectal Cancer(1/19/2010) Researchers from the UK and Canada have reported that a review of five trials confirms the effectiveness of adding Avastin® (bevacizumab) to chemotherapy for the treatment of advanced colorectal cancer. The details of this review appeared in an early online publication in the Annals of Oncology on November 25, 2009.
Home Care Nursing Improves Symptom Management(12/7/2009) Researchers from the UK have reported that symptom management for patients with breast and colorectal cancer treated with oral Xeloda® (capecitabine) was better for patients who received home care nursing than for patients receiving standard care. The results of this study appeared in an early online publication in the Journal of Clinical Oncology on November 16, 2009.
Erbitux® Improves Response Rate to Chemotherapy for Colorectal Liver Metastases(11/30/2009) Researchers from Germany and Austria have reported that the addition of Erbitux® (cetuximab) to FOLFOX6 or FOLFIRI improves response rates of patients with hepatic colorectal metastasis, which allows for more effective surgical resection. The details of this study appeared early online on November 25, 2009 in Lancet Oncology.
Patient Home
